Combining Immunotherapy With Radiation Oncology in NSCLC

Commentary
Video

Terrence T. Sio, MD, MS, emphasizes multidisciplinary collaboration for treating patients with NSCLC who may require more than 1 type of therapy.

In a conversation with CancerNetwork®, Terence T. Sio, MD, MS, highlighted radiation oncology treatment decision-making strategies for patients with non–small cell lung cancer (NSCLC), including for those who may be eligible to receive immunotherapy.

According to Sio, a professor of radiation oncology at Mayo Clinic in Phoenix, Arizona, it is crucial to consider potential toxicities, such as pneumonia and factors such as tumor size when administering radiation therapy to patients with NSCLC. Additionally, he emphasized multidisciplinary collaboration across different departments at his institution to optimize treatment courses for those who may require more than 1 type of therapy.


Transcript:

There is a lot of very good biology that is now being used for helping our patients and getting targeted [treatment] for that cancer. These are very specific treatments that may involve targets such as EGFR or KRAS mutations. There are now also new advances on the horizon [involving] combining immunotherapy, too.

These medications, and how the treatments are needed to be used for our patients, make a difference in terms of the decisions that we may make as a radiation oncologist for our [patients with] lung cancer. Depending on how big the tumor may be and the number of lung and heart tissues that will be exposed to radiation therapy, it is important to balance the risks. How likely is it for an injury like pneumonia or what we call radiation-induced pneumonitis to happen in this setting? It is very important [to have] multidisciplinary treatment and consultation with our surgeons and our medical oncologists. At our institutions, tumor boards are being held at regular intervals weekly. There are a lot of cross disciplinary discussions among different doctors to make sure that we're providing the best method for helping our patients who will very likely need more than 1 treatment, or [more than] 1 doctor's care if they have stage III non–small cell lung cancer.

Recent Videos
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Related Content